Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,855,355.00 in Stock

Key Points

• United Therapeutics CEO Martine Rothblatt sold 9,500 shares at an average price of $511.09, generating $4.86 million; her remaining direct stake is valued at approximately $165.8 million.
• United Therapeutics shares rose 0.5% to $512.70, while the company’s latest quarterly earnings of $7.27 per share exceeded analyst expectations, despite revenue declining 1.9% year over year.
• Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a consensus price target of $646, while institutional investors own 94.08% of the company.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $165,819,572.87. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Up 0.5%

Shares of UTHR stock traded up $2.32 on Tuesday, reaching $512.70. 456,329 shares of the stock were exchanged, compared to its average volume of 488,812. The stock has a market cap of $21.99 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The firm has a 50 day moving average of $529.90 and a two-hundred day moving average of $539.42. United Therapeutics Corporation has a 1-year low of $375.61 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $6.41 earnings per share. On average, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently modified their holdings of UTHR. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock valued at $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in shares of United Therapeutics during the second quarter worth approximately $277,000. Cerity Partners LLC boosted its position in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock worth $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia grew its holdings in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock worth $468,000 after buying an additional 105 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on UTHR shares. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday. Finally, Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source